Checkmate 9ER: A New Arrow in Our Quiver

The results of Phase 3 Checkmate 9ER trial are in! The 9ER trial evaluated the combination of Nivolumab (“Nivo”) and Cabozantinib (“Cabo”). This trial compared the combo to Sunitinib (“Sutent”) in patients who had not previously been on a drug and who had disease that had spread or metastasized.

Nivo is an immunotherapy agent that helps your immune system recognize and mobilize your T-cells to attack the cancer cells. Cabo is a TKI (tyrosine kinase inhibition) drug. The combo improved progression free survival (PFS), meaning the cancer did not progress as quickly compared to the other drug. It also improved OS (overall survival) in patients previously untreated. There were 651 patients in the trial. Nivo and Cabo are each approved by the FDA. This new combo is not yet approved, but will likely be approved in the near future. Other good news is that patient’s toxicity to the drug combo and their quality of life was improved. As soon as this combination is approved, it will give patients another option in their arsenal to battle mRCC.

Read the 2020 ESMO News Release here.

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer

Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer

Deb Beyhan is the Patient Legislative Advocate for KidneyCAN. She was diagnosed with stage IV kidney cancer in 2016 at the age of 53. Deb lives outside of Atlanta, GA, with her husband.    For this month's Community Spotlight, we want to tell you about a member of our volunteer team, Deb Beyhan....

DISTRICT DAYS 2022 →

SPRING ADVOCACY DAYS 2022 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

District Days: Asking Congress to Fund Kidney Cancer Research

District Days: Asking Congress to Fund Kidney Cancer Research

On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event and how you can help fund...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING YOUR CARE TEAM

TREATMENT & TRIAL OPTIONS

LIVING WELL WITH KIDNEY CANCER

CLINICAL TRIALS →

IMMUNOTHERAPY →

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

The 2022 Kidney Cancer Research Summit

The 2022 Kidney Cancer Research Summit

Dr. Laurence Albiges (Institut Gustave Roussy) presents on the microbiome at KCRS22. The microbiome has now been recognized as one of the emerging hallmarks and enabling characteristics of cancer. KidneyCAN hosted the 4th Annual Kidney Cancer Research Summit on October 6-7, 2022  live in...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Rock the Run for Kidney Cancer Research Funding

Rock the Run for Kidney Cancer Research Funding

KidneyCAN had the first ever Rock the Run 5k fundraiser in October 2022. This is part of the group of KCRS22 attendees who walked and ran with us at dawn before the second conference day began. KidneyCAN is proud to share the results of the first annual Rock the Run 5K fundraiser. Our Purpose...